Teriflunomide
( DrugBank: Teriflunomide / KEGG DRUG: Teriflunomide )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis | 302 |
| 25 | Progressive multifocal leukoencephalopathy | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 26 | HTLV-1-associated myelopathy | 1 |
| 63 | Idiopathic thrombocytopenic purpura | 1 |
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
25. Progressive multifocal leukoencephalopathy
Clinical trials : 28 / Drugs : 31 - (DrugBank : 20) / Drug target genes : 7 - Drug target pathways : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
26. HTLV-1-associated myelopathy
Clinical trials : 32 / Drugs : 46 - (DrugBank : 27) / Drug target genes : 35 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
63. Idiopathic thrombocytopenic purpura
Clinical trials : 575 / Drugs : 261 - (DrugBank : 64) / Drug target genes : 61 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|